Relationship between compliance with ophthalmic examinations preoperatively and visual outcome after vitrectomy for proliferative diabetic retinopathy

Japanese Journal of Ophthalmology

Volumn 56, Issue 5, 2012, Pages 481-487

  Itoh Tanimura, Machiko ^a   Hirakata, Akito ^a   Itoh, Yuji ^a   Sano, Milena Eimi ^a   Inoue, Makoto ^a   Ishida, Hitoshi ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Compliance; Diabetic retinopathy; Ophthalmic examination; Surgical outcome; Vitreoretinal surgery

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; EYE EXAMINATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

ADULT; AGED; BLOOD GLUCOSE; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; TREATMENT OUTCOME; VISION TESTS; VISUAL ACUITY; VITRECTOMY;

EID: 84866743319     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-012-0161-4     Document Type: Article

References (24)

1. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105:998-1003.
2. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007; 14:179-83.
3. Stefánsson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E. Screening and prevention of diabetic blindness. Acta Ophthalmol Scand. 2000; 78:374-85.
4. The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol. 1976; 81:383-96.
5. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology. 1981; 88:583-600.
6. Chew EY, Ferris FL 3rd, Csaky KG, Murphy RP, Agrón E, Thompson DJ, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology. 2003; 110:1683-9.
7. Brechner RJ, Cowie CC, Howie LJ, Herman WH, Will JC, Harris MI. Ophthalmic examination among adults with diagnosed diabetes mellitus. JAMA. 1993; 270:1714-8.
8. Schoenfeld ER, Greene JM, Wu SY, Leske MC. Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program. Ophthalmology. 2001; 108:563-71.
9. Soto-Pedre E, Hernaez-Ortega MC, Piniés JA. Duration of diabetes and screening coverage for retinopathy among patients with type 2 diabetes. Ophthalmic Epidemiol. 2007; 14:76-9.
10. Klein R. Prevention of visual loss from diabetic retinopathy. Surv Ophthalmol. 2002; 47(suppl 2):S246-52.
11. Younis N, Broadbent DM, Vora JP. Liverpool Diabetic Eye Study. incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003; 361(9353):195-200.
12. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992; 15:1875-91.
13. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009; 32(suppl 1):S13-61.
14. Mason JO 3rd, Nixon PA, White MF. intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006; 142:685-8.
15. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006; 113:1695.e1-15.
16. Lecaire T, Palta M, Zhang H, Allen C, Klein R, D'Alessio D. Lower-than-expected prevalence and severity of retinopathy in an incident cohort followed during the first 4-14 years of type 1 diabetes: the Wisconsin Diabetes Registry Study. Am J Epidemiol. 2006; 164:143-50.
17. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVii. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998; 105: 1801-15.
18. Henricsson M, Nilsson A, Groop L, Heijl A, Janzon L. Prevalence of diabetic retinopathy in relation to age at onset of the diabetes, treatment, duration and glycemic control. Acta Ophthalmol Scand. 1996; 74:523-7.
19. ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, ACCORD trial group, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010; 376(9739):419-30.
20. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXii the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008; 115:1859-68.
21. Brown JB, Pedula KL, Summers KH. Diabetic retinopathy: contemporary prevalence in a well-controlled population. Diabetes Care. 2003; 26:2637-42.
22. Paz SH, Varma R, Klein R, Wu J. Los Angeles Latino Eye Study Group. Noncompliance with vision care guidelines in Latinos with type 2 diabetes mellitus: the Los Angeles Latino Eye Study. Ophthalmology. 2006; 113:1372-7.
23. Klein R, Klein BE, Jensen SC, Moss SE. The relation of socioeconomic factors to the incidence of proliferative diabetic retinopathy and loss of vision. Ophthalmology. 1994; 101:68-76.
24. Newcomb PA, Klein R, Massoth KM. Education to increase ophthalmologic care in older onset diabetes patients: indications from the Wisconsin Epidemiologic Study of Diabetic Retinopathy. J Diabetes Complicat. 1992; 6:211-7.